Aclaris Therapeutics, Inc.’s ACRS share price has surged by 6.72%, which has investors questioning if this is right time to sell.

Researchers have found in a new research that children with inflammatory skin conditions such as atopic dermatitis, psoriasis ...

Pelthos Therapeutics, a Durham-based wholly owned subsidiary of Ligand Pharmaceuticals (Nasdaq: LGND), is combining with ...

Kymera Therapeutics, Inc.’s KYMR share price has surged by 5.21%, which has investors questioning if this is right time to sell.

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Complete BiomX Inc. stock information by Barron's. View real-time PHGE stock price and news, along with industry-best analysis.

Children with early-onset atopic dermatitis (AD) have an elevated risk for pediatric uveitis, according to a study published ...

BiomX Inc. company and executive profile by Barron's. View the latest PHGE company infomation and executive bios.

Dermatology providers reported strong impacts on the work and home life of patients with moderate to severe chronic hand eczema, a manifestation of atopic dermatitis.

Tralokinumab use in patients with head and neck atopic dermatitis was associated with sustained improvements with up to 4 years of treatment.

The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Aclaris ...

A research team at Korea University Medical School discovered a gene-regulating substance called 'miR-4497', which was ...